The drug olaparib (Lynparza) reduced the chances of cancer progression by about 42 percent in women with breast cancer linked to BRCA1 and BRCA2 gene mutations, according to the study. Olaparib delayed cancer progression by about three months. The drug also caused tumors to shrink in three out
